Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting Sep 14, 2025
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting Sep 3, 2025
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments Aug 12, 2025
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers Jun 11, 2025
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments May 13, 2025
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 Apr 29, 2025
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments Mar 31, 2025
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants Dec 20, 2024
